"Hyperlipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions with excess LIPIDS in the blood.
| Descriptor ID |
D006949
|
| MeSH Number(s) |
C18.452.584.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipidemias".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipidemias".
This graph shows the total number of publications written about "Hyperlipidemias" by people in this website by year, and whether "Hyperlipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 1 | 3 |
| 1997 | 2 | 0 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 3 | 5 |
| 2002 | 6 | 1 | 7 |
| 2003 | 1 | 4 | 5 |
| 2004 | 7 | 4 | 11 |
| 2005 | 6 | 4 | 10 |
| 2006 | 4 | 2 | 6 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 4 | 7 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 4 | 3 | 7 |
| 2014 | 2 | 4 | 6 |
| 2015 | 6 | 4 | 10 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 2 | 4 |
| 2018 | 6 | 1 | 7 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 2 | 5 |
| 2021 | 3 | 1 | 4 |
| 2022 | 8 | 0 | 8 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipidemias" by people in Profiles.
-
Comparative and combination study of simvastatin alone and in combination with Beta vulgaris in hyperlipidemia patients. Pak J Pharm Sci. 2024 Sep; 37(5):1033-1041.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):913-925.
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):899-912.
-
Association of Atherosclerotic Cardiovascular Disease, Hypertension, Diabetes, and Hyperlipidemia With Gulf War Illness Among Gulf War Veterans. J Am Heart Assoc. 2023 10 03; 12(19):e029575.
-
Update on management of paediatric dyslipidaemia. Curr Opin Endocrinol Diabetes Obes. 2023 02 01; 30(1):52-64.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023 01; 25(1):31-41.
-
Primary Prevention Management of Elevated Lipoprotein(a). JAMA Cardiol. 2023 01 01; 8(1):96-97.
-
Severe hypercholesterolemia in a patient with very low albumin and normal renal function. J Clin Lipidol. 2023 Jan-Feb; 17(1):64-67.
-
Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling. High Blood Press Cardiovasc Prev. 2022 Nov; 29(6):601-610.
-
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):617-625.